Exelixis (EXEL) Receivables - Other (2010 - 2021)
Exelixis (EXEL) posted quarterly Receivables - Other of $9.7 million for Q3 2021, down 29.36% year-over-year from $13.8 million in Q3 2020, and down 29.36% quarter-over-quarter from $13.8 million in Q3 2020.
Analysis
Exelixis (EXEL) Receivables - Other (2010 - 2021) Analysis & Trends
Exelixis' Receivables - Other history runs 10 years deep, the most recent figure standing at $9.7 million for Q3 2021.
- In Q3 2021, Receivables - Other fell 29.36% year-over-year to $9.7 million; the TTM figure through Jul 2021 stood at $9.7 million (down 29.36% YoY), while the FY2020 annual figure was $1.1 million, down 75.92% from the prior year.
- Receivables - Other for Q3 2021 stood at $9.7 million, down from $13.8 million in the prior quarter.
- The five-year high for Receivables - Other was $31.8 million in Q1 2018, with the low at -$8.7 million in Q1 2019.
- The 5-year median for Receivables - Other is $11.1 million (2019), against an average of $10.4 million.
- The sharpest annual moves came in 2019 and 2020: Receivables - Other plunged 127.45% in 2019, then gained 11.38% in 2020.
- Exelixis' Receivables - Other stood at $3.9 million in 2017, then tumbled by 62.18% to $1.5 million in 2018, then jumped by 837.57% to $13.8 million in 2019, then slipped by 0.01% to $13.8 million in 2020, then dropped by 29.36% to $9.7 million in 2021.
- Business Quant data shows EXEL's Receivables - Other at $9.7 million in Q3 2021, $13.8 million in Q3 2020, and $1.1 million in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 2, 2021 | 9.75 Mn |
| Jul 3, 2020 | 13.80 Mn |
| Jan 3, 2020 | 1.06 Mn |
| Sep 27, 2019 | 13.80 Mn |
| Jun 28, 2019 | 12.39 Mn |
| Mar 29, 2019 | -8.74 Mn |
| Dec 28, 2018 | 1.47 Mn |
| Sep 28, 2018 | 24.49 Mn |
| Mar 30, 2018 | 31.84 Mn |
| Dec 29, 2017 | 3.89 Mn |
| Mar 31, 2014 | 516,000.00 |
| Dec 31, 2013 | -1.23 Mn |
| Sep 30, 2013 | 962,000.00 |
| Jun 30, 2013 | 344,000.00 |
| Mar 31, 2013 | 1.11 Mn |
| Dec 31, 2012 | 44,000.00 |
| Sep 30, 2012 | 2.71 Mn |
| Jun 30, 2012 | 2.28 Mn |
| Mar 31, 2012 | -27.87 Mn |
| Dec 31, 2011 | 25.54 Mn |